Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study

Acta Diabetologica

Volumn 52, Issue 1, 2015, Pages 103-112

  Then, Cornelia ^a,b   Kowall, Bernd ^c   Lechner, Andreas ^a,b   Meisinger, Christa ^d   Heier, Margit ^d   Koenig, Wolfgang ^e   Peters, Annette ^d   Rathmann, Wolfgang ^c   Seissler, Jochen ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

AVP; Diabetes; Hypertension; Metabolic syndrome; Sex differences; Vasopressin

Indexed keywords

COPEPTIN; GLYCOPEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HEALTH SURVEY; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLYCOPEPTIDES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; SEX FACTORS; TRIGLYCERIDES;

EID: 84928880091     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0609-8     Document Type: Article

References (25)

1. Morgenthaler NG (2010) Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 16(Suppl 1):S37–S44. doi:10.1111/j.1751-7133.2010.00177.x
2. Holmes CL, Landry DW, Granton JT (2004) Science review: vasopressin and the cardiovascular system part 2—clinical physiology. Crit Care 8(1):15–23. doi:10.1186/cc2338
3. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A (2007) Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148(5):2075–2084
4. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119. doi:10.1373/clinchem.2005.060038
5. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ (2009) Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94(7):2558–2564. doi:10.1210/jc.2008-2278
6. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96(7):E1065–E1072. doi:10.1210/jc.2010-2981
7. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121(19):2102–2108. doi:10.1161/CIRCULATIONAHA.109.909663
8. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ (2012) Sex differences in the association between plasma copeptin and incident type 2 diabetes: the prevention of renal and vascular endstage disease (PREVEND) study. Diabetologia 55(7):1963–1970. doi:10.1007/s00125-012-2545-x
9. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5(4):e10100. doi:10.1371/journal.pone.0010100
10. Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, Peters A, Thiery J, Rathmann W, Seissler J (2013) Plasma copeptin levels are inversely associated with intima-media-thickness in men: the population-based KORA F4 study. Cardiovasc Diabetol 12(1):168. doi:10.1186/1475-2840-12-168
11. Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, Peters A, Roden M, Lechner A, Kowall B, Rathmann W (2012) Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol 167(6):847–853. doi:10.1530/EJE-12-0472
12. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, Meisinger C (2009) Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 26(12):1212–1219. doi:10.1111/j.1464-5491.2009.02863.x
13. Meisinger C, Ruckert IM, Rathmann W, Doring A, Thorand B, Huth C, Kowall B, Koenig W (2011) Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the cooperative health research in the region of Augsburg (KORA) F4 study. Diabetes Care 34(7):1648–1650. doi:10.2337/dc11-0118
14. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46(2):182–189. doi:10.1007/s00125-002-1025-0
15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644
16. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 37(4):598–603. doi:10.1038/ijo.2012.88
17. Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT (2013) Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. doi:10.1007/s00125-013-2922-0
18. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257–263. doi:10.1042/CS20080140
19. Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36(11):3639–3645. doi:10.2337/dc13-0683
20. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG (1985) The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf) 22(4):463–468
21. Wang YX, Edwards RM, Nambi P, Stack EJ, Pullen M, Share L, Crofton JT, Brooks DP (1993) Sex difference in the antidiuretic activity of vasopressin in the rat. Am J Physiol 265(6 Pt 2):R1284–R1290
22. Enhorning S, Leosdottir M, Wallstrom P, Gullberg B, Berglund G, Wirfalt E, Melander O (2009) Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 89(1):400–406. doi:10.3945/ajcn.2008.26382
23. Stallone JN (1993) Role of endothelium in sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol 265(6 Pt 2):H2073–H2080
24. Wang YX, Crofton JT, Liu H, Sato K, Share L (1996) V2-receptor blockade enhances pressor response to vasopressin: gender difference. Life Sci 59(8):695–703. doi:10.1016/0024-3205(96)00351-7
25. Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL (2001) Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol 91(4):1893–1901